


Amendments to the Claims:

This listing of claims replaces all prior versions and listings of claims in the application:

Listing of Claims:

1-66. (cancelled)

67. (previously presented) A double-stranded compound comprising a sense strand and an antisense strand, wherein each strand comprises 12-35 nucleotides and wherein said compound comprises at least one locked nucleic acid (LNA) monomer having the structure



wherein

X is selected from the group consisting of 0, S and NR", where R" is H or C₁₋₄ alkyl;

B is a nucleobase;

Z and Z* are independently absent or selected from the group consisting of an internucleoside linkage group, a terminal group and a protection group; so that when the LNA monomer is located at the 3' end, Z is a terminal group and Z* is an internucleoside linkage group; when the LNA monomer is located at the 5' end, Z is absent and Z* is a terminal group; and when the

LNA monomer is located within the nucleotide sequence, Z is absent and Z* is an internucleoside linkage group.

68. (previously presented) The compound according to claim 67, wherein the sense strand comprises at least one LNA monomer.

69. (previously presented) The compound according to claim 68, wherein the sense strand comprises 1-10 LNA monomers.

70. (previously presented) The compound according to claim 68, wherein at least one LNA monomer is located at the 5' end of the sense strand.

71. (previously presented) The compound according to claim 70, wherein at least two LNA monomers are located at the 5' end of the sense strand.

72. (previously presented) The compound according to claim 67, wherein at least one LNA monomer is located at the 3' end of the sense strand.

73. (previously presented) The compound according to claim 72, wherein at least two LNA monomers are located at the 3' end of the sense strand.

74. (previously presented) The compound according to claim 67, wherein the antisense strand comprises at least one LNA monomer.

75. (previously presented) The compound according to claim 74, wherein the antisense strand comprises 1-10 LNA monomers.

76. (previously presented) The compound according to claim 74, wherein at least one LNA monomer is located at the 3' end of the antisense strand.

77. (previously presented) The compound according to claim 76, wherein at least two LNA monomers are located at the 3' end of the antisense strand.

78. (previously presented) The compound according to claim 77, wherein at least three LNA monomers are located at the 3' end of the antisense strand.

79. (previously presented) The compound according to claim 67, wherein no LNA monomer is located at the 5' end of the antisense strand.

80. (previously presented) The compound according to claim 67, wherein the sense strand comprises at least one LNA and the antisense strand comprises at least one LNA monomer.

81. (previously presented) The compound according to claim 80, wherein the sense strand comprises 1-10 LNA monomers and the antisense strand comprises 1-10 LNA monomers.

82. (previously presented) The compound according to claim 80, wherein the sense strand comprises at least one LNA monomer at the 5' end and at least one LNA monomer at the 3' end, and wherein the antisense strand comprises at least one LNA monomer at the 3' end.

83. (previously presented) The compound according to claim 82, wherein the sense strand comprises at least one LNA monomer at the 5' end and at least one LNA monomer at the 3' end, and wherein the antisense strand comprises at least two LNA monomers at the 3' end.

84. (previously presented) The compound according to claim 83, wherein the sense strand comprises at least two LNA monomers at the 5' end and at least two LNA monomers at the 3' end, and wherein the antisense strand comprises at least two LNA monomers at the 3' end.

85. (previously presented) The compound according to claim 84, wherein the sense strand comprises at least two LNA monomers at the 5' end and at least two LNA monomers at the 3' end, and wherein the antisense strand comprises at least three LNA monomers at the 3' end.

86. (previously presented) The compound according to claim 80, wherein no LNA monomer is located at the 5' end of the antisense strand.

87. (previously presented) The compound according to claim 67, wherein the sense strand comprises at least one LNA monomer in at least one of the positions 9-13 counted from the 5' end.

88. (previously presented) The compound according to claim 87, wherein the sense strand comprises a LNA monomer in position 10.

89. (previously presented) The compound according to claim 87, wherein the sense strand comprises a LNA monomer in position 11.

90. (previously presented) The compound according to claim 87, wherein the sense strand comprises a LNA monomer in position 12.

91. (previously presented) The compound according to claim 67, wherein each strand comprises 17-25 nucleotides.

92. (previously presented) The compound according to claim 91, wherein each strand comprises 20-22 nucleotides.

93. (previously presented) The compound according to claim 67, wherein at least one of the strands has a 3' overhang.

94. (previously presented) The compound according to claim 67, wherein X is selected from the group consisting of O, S and NH.

95. (previously presented) The compound according to claim 94, wherein X is O.

96. (previously presented) The compound according to claim 67, wherein said LNA monomer is in the beta-D form

97. (previously presented) A pharmaceutical composition comprising the compound according to claim 67 and a pharmaceutically acceptable diluent, carrier or adjuvant.

98-101. (cancelled)

102. (**new**) The compound according to claim 88 wherein the nucleobase of the LNA monomer at position 10 is thymine (T).